Investigating how genetic factors influence immune response in melanoma treatment
Project 2
This study is looking at how your genes might influence how well your immune system responds to treatments for melanoma, like ipilimumab and nivolumab, and it hopes to find clues that can help predict how long you might stay cancer-free after treatment, so your participation by providing genetic samples could really help improve future therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11196467 on NIH RePORTER |
What this research studies
This research focuses on understanding how inherited genetic factors affect the immune response in melanoma patients receiving immune checkpoint inhibitor therapies. It aims to identify biomarkers that can predict relapse-free survival after treatment with drugs like ipilimumab and nivolumab. By examining the genetic variations that influence T-cell function, the study seeks to uncover new targets for more effective adjuvant therapies. Patients may be involved in providing genetic samples to help identify these important biomarkers.
Who could benefit from this research
Good fit: Ideal candidates for this research are melanoma patients who have undergone or are undergoing immune checkpoint inhibitor therapy.
Not a fit: Patients who have not been diagnosed with melanoma or are not receiving immune checkpoint inhibitor therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to personalized treatment strategies that improve survival rates for melanoma patients.
How similar studies have performed: Previous research has shown promise in identifying genetic factors that influence immune responses, suggesting that this approach could yield valuable insights.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Kirchhoff, Tomas — New York University School of Medicine
- Study coordinator: Kirchhoff, Tomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.